

Nanexa invites to a webcast to present the positive clinical data from NEX-22 once monthly GLP-1, liraglutide project published on last Friday

Referring to the clinical results presented last Friday Nanexa invites to a webcast hosted by Infront Direkt studios at 14:00 pm today, Monday November 25th.

Chairman Dr. Göran Ando, CEO David Westberg and Director Business Development Otto Skolling will present the results as well as an overview of the GLP-1 segment and plans going forward. "These clinical results put us in a completely new, very exciting situation with a potential to transform the type-2 diabetes and obesity treatment regime to less frequent treatments say David Westberg, CEO Nanexa."

The comment will be available [here](#).
Viewers will have the opportunity to ask questions via chat.

The comment will also be published on Nanexa's website afterwards.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com

The company's Certified Adviser is Carnegie Investment Bank AB (publ).

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

[Nanexa invites to a webcast to present the positive clinical data from NEX-22 once monthly GLP-1, liraglutide project published on last Friday](#)